Nevro Corp (NYSE:NVRO) was the recipient of unusually large options trading activity on Thursday. Traders bought 567 call options on the company. This is an increase of approximately 845% compared to the typical volume of 60 call options.
In related news, Director Wilfred E. Jaeger sold 14,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $83.28, for a total value of $1,204,062.24. Following the completion of the transaction, the director now owns 1,518 shares of the company’s stock, valued at approximately $126,419.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Wilfred E. Jaeger sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $80.48, for a total transaction of $804,800.00. Following the completion of the transaction, the director now directly owns 1,518 shares of the company’s stock, valued at approximately $122,168.64. The disclosure for this sale can be found here. Insiders sold a total of 234,116 shares of company stock valued at $18,913,822 in the last ninety days. Company insiders own 12.10% of the company’s stock.
Large investors have recently modified their holdings of the business. Hershey Trust Co. acquired a new stake in shares of Nevro during the 4th quarter valued at $119,000. Public Employees Retirement Association of Colorado acquired a new stake in shares of Nevro during the 4th quarter valued at $160,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Nevro during the 3rd quarter valued at $211,000. Glenmede Trust Co. NA acquired a new stake in shares of Nevro during the 4th quarter valued at $237,000. Finally, HBK Investments L P acquired a new stake in shares of Nevro during the 4th quarter valued at $255,000.
Shares of NYSE:NVRO opened at $86.52 on Friday. The firm has a market cap of $2,615.81, a price-to-earnings ratio of -69.22 and a beta of -0.53. Nevro has a 12-month low of $65.00 and a 12-month high of $97.70. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.61 and a quick ratio of 5.91.
Nevro (NYSE:NVRO) last issued its earnings results on Thursday, February 22nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The company had revenue of $97.96 million for the quarter, compared to analyst estimates of $96.87 million. Nevro had a negative net margin of 11.22% and a negative return on equity of 15.01%. The company’s quarterly revenue was up 38.9% on a year-over-year basis. During the same period last year, the business earned ($0.34) EPS. equities analysts forecast that Nevro will post -0.76 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Nevro Sees Unusually Large Options Volume (NVRO)” was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3336721/nevro-sees-unusually-large-options-volume-nvro.html.
Nevro Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.